INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY WORLD HEALTH ORGANIZATION TOXICOLOGICAL EVALUATION OF SOME FOOD COLOURS, EMULSIFIERS, STABILIZERS, ANTI-CAKING AGENTS AND CERTAIN OTHER SUBSTANCES FAO Nutrition Meetings Report Series No. 46A WHO/FOOD ADD/70.36 The content of this document is the result of the deliberations of the Joint FAO/WHO Expert Committee on Food Additives which met in Rome, 27 May - 4 June 19691 Food and Agriculture Organization of the United Nations World Health Organization 1 Thirteenth report of the Joint FAO/WHO Expert Committee on Food Additives, FAO Nutrition Meetings Report Series, in press; Wld Hlth Org. techn. Rep. Ser., in press. RIBOFLAVIN Biological Data Biochemical aspects Riboflavin is essential for all animals and many micro-organisms. Riboflavin-5-phosphate is the prosthetic group of flavoproteins involved in general cell metabolism as hydrogen acceptors. The recommended daily dietary allowance1 (U.S. Food and Nutrition Board, 1968). The recommended therapeutic doses for treatment or prevention of riboflavin deficiency are: 1968 BP and 1963 BPC 1965 USP XVII Therapeutic dose 5-10 mg/day 10-15 mg/day Prophylactic dose 1-4 mg/day 2 mg/day Crystalline riboflavine was recovered from the bladder and ureters of rats a few hours after i.v. injection of a saturated solution in saline. Nephrectomized rats accumulated injected riboflavin in the small intestine through excretion from the jejunal mucosa. The large intestine destroyed riboflavin (Selye, 1943). Normal man excretes unchanged riboflavin in faeces and urine (Axelrod et al., 1941).2 Human deficiency is indicated by adult urinary excretion of less than 10 µg/6 hours (Harrison et al., 1962). The total amount absorbed by man never exceeds 15 - 20 mg per day. 1 For man is about 1.5 mg/day (pregnant women 1.8 mg/day, lactating women 2.0 mg/day). 2 The urinary recovery after oral administration to fasted normal humans decreased with higher doses, but administration immediately after breakfast resulted in a constant per cent of urinary recovery independent of dose (Levy & Jusko, 1966). Acute toxicity Compound Animal Route LD50 Reference mg/kg body-weight Riboflavin mouse i.p. > 340 Kuhn & Boulanger, 1936 rat oral3 >10 000 Unna & Greslin, 1942 s.c. 5 000 Unna & Greslin, 1942 i.p. 560 Unna & Groslin, 1942 dog oral > 2 000 Unna & Greslin, 1942 Sodium riboflavinate rat oral >10 000 Unna & Greslin, 1942 s.c. 790 Unna & Greslin, 1942 i.p. 560 Unna & Greslin, 1942 3 Oral > 10 000, Pellmont, 1962; i.v. 50 -100, Pellmont, 1962. The high oral LD50 in rats is probably due to poor absorption from the gastro-intestinal tract and the low solubility of riboflavin. Parenteral administration of 0.6 g/kg body-weight leads to renal obstruction of pelvis and collecting tubules crystals of riboflavin with death from renal failure and weight less. Toxicity is similar to pyridoxine or pantothenic acid (Unna & Greslin, 1942). Short-term studies Rat. 10 mg/day fed to male and female rats over 20 weeks after weaning in 3 successive generations produced no apparent adverse effect on growth and reproduction. No pathological changes were observed (Unna & Greslin, 1942). Dog. Four dogs fed 25 mg/kg body-weight/day for, 5 months showed no adverse effects or pathological changes (Unna & Greslin, 1942). Comments Animals fed high doses of riboflavin show no toxic effects. There are numerous biochemical studies and a vast amount of clinical and nutritional data on riboflavin. It is reasonable to use this information for evaluation. EVALUATION Level causing no toxicological effect in the rat 50 mg/kg body-weight per day. Estimate of acceptable daily intake for man mg/kg body-weight Unconditional acceptance 0 - 0.5 REFERENCES Axelrod, A. E., Spies, T. D. & Elvehjem, C. A. & Axelrod, V. (1941) J. clin. Invest., 20, 229 British Pharmaceutical Codex 1963 British Pharmacopoeia 1968 Emmerie, A. (1938) Acta. brev. neerl. Physiol., 8, 116 Food & Nutrition Board (1968) Publication 1694, National Academy of Science N.R.C., Washington, D.C. Harrison, T. R. (1962) Principles of Internal Medicine, 4th edn., 537, McGraw-Hill, N.Y., Toronto & London Khun, R. & Boulanger, P. (1936) Hoppe-Seylers Z. physiol. Chem.,241, 233 Koschara, W. (1935) Hoppe-Seylers Z. physiol. Chem., 232, 101 Levy, G. & Jusko, W. J. (1966) J. Pharm. Sci 55, 285 Pellmont (1962) Handbuch der allgemeinen Pathologie Band 11, pp. 984, Springer Verlag, Berlin Selye, H. (1943) J. Nutr., 25, 137 United States Pharmacopoeia, seventeenth revision, 1965 Unna, K. & Greslin, J. G. (1942) J. Pharmacol. exp. Ther., 76, 75
See Also: Toxicological Abbreviations Riboflavin (ICSC) RIBOFLAVIN (JECFA Evaluation)